Please login to the form below

Not currently logged in
Email:
Password:

PhRMA objects to House bill

PhRMA is taking issue with parts of the House war supplemental bill that would prevent patent settlements between drugmakers

Pharmaceutical Research and Manufacturers of America (PhRMA) is taking issue with language in the House war supplemental bill that would prevent patent settlements between brand-name and generic drugmakers.

The settlements, often referred to as "pay for delay" deals, have attracted negative attention for allowing brand-name pharma firms to pay generics companies to delay bringing lower-cost versions of brand-name drugs to market. However, PhRMA maintains that the settlements are "pro-consumer" and "often bring generics to market years before patent expiration."

"PhRMA continues to believe that legislation that would impose a blanket ban on certain types of patent settlements or otherwise prevent them could decrease the value of patents and reduce incentives for future innovation of new medicines," the trade group said in a statement.

"The courts and enforcement agencies like the Federal Trade Commission (FTC) are in the best position to review these settlements on a case-by-case basis to ensure that they are not harmful to competition," PhRMA stressed.

"By imposing a general ban or imposing harsh disincentives, pending legislation would effectively remove the decision-making process from this appropriate venue."

The pending bill is intended to address supplemental appropriations for the wars in Iraq and Afghanistan. However, such bills frequently end up with other provisions attached to them.

29th June 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics